Pediatrix Medical Group, Inc. (BMV:MD)
Mexico · Delayed Price · Currency is MXN | Market Cap | 35.51B +40.1% |
| Revenue (ttm) | 34.08B +0.5% |
| Net Income | 3.05B +59.0% |
| EPS | 36.67 +62.2% |
| Shares Out | n/a |
| PE Ratio | 11.62 |
| Forward PE | 11.19 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 38 |
| Open | 447.00 |
| Previous Close | 323.00 |
| Day's Range | 447.00 - 447.00 |
| 52-Week Range | 297.00 - 447.00 |
| Beta | 0.65 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Pediatrix Medical Group
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to expectant mothers and unborn babies through its affiliated maternal-fe... [Read more]
News
Pediatrix Medical downgraded to Hold from Buy at Jefferies
Jefferies downgraded Pediatrix Medical (MD) to Hold from Buy with a price target of $28, up from $27. The firm sees a more neutral risk/reward with the shares up 150%…
Pediatrix Medical price target raised to $28 from $25 at UBS
UBS analyst AJ Rice raised the firm’s price target on Pediatrix Medical (MD) to $28 from $25 and keeps a Neutral rating on the shares.
Pediatrix Medical price target raised to $25 from $19 at Deutsche Bank
Deutsche Bank analyst Pito Chickering raised the firm’s price target on Pediatrix Medical (MD) to $25 from $19 and keeps a Hold rating on the shares.
Pediatrix Medical Group Earnings Call Transcript: Q2 2026
Adjusted EBITDA reached $76M in Q2 2026, with revenue up 4% year-over-year, driven by improved payer mix, RCM collections, and higher acuity. Full-year EBITDA guidance is reaffirmed, and share repurchases continue as the company focuses on tele-hybrid medicine and acquisition opportunities.
Pediatrix Medical Group Quarterly report: Q2 2026
Pediatrix Medical Group has published its Q2 2026 quarterly earnings report on August 4, 2026.
Pediatrix Medical Group Earnings release: Q2 2026
Pediatrix Medical Group released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Pediatrix Medical sees 2026 adjusted EBITDA $280M-$300M
06:10 EDT Pediatrix Medical (MD) sees 2026 adjusted EBITDA $280M-$300M
Pediatrix Medical Group Reports Second Quarter Results
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Reports Second Quarter Results.
Pediatrix Medical backs FY26 adjusted EBITDA view $280M-$300M
Pediatrix Medical (MD) Group provided an update on its second quarter 2026 business trends. In response to recent reports from other healthcare market participants regarding shifting utilization and r...
Pediatrix Medical Group Provides Second Quarter Update
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group, Inc. (NYSE: MD) (“Pediatrix” or “the Company”), a leading provider of physician services, today provided an update on its secon...
Pediatrix Medical price target raised to $28 from $23 at Truist
Truist raised the firm’s price target on Pediatrix Medical (MD) to $28 from $23 and keeps a Hold rating on the shares as part of a broader research note previewing…
New CV APP Compensation and Utilization Survey Report Highlights Growing APP Contributions, Prompting Focus on Support and Compensation
JACKSONVILLE BEACH, Fla.--(BUSINESS WIRE)--MedAxiom, the premier source for cardiovascular organizational performance solutions, has released the 2025 Cardiovascular Advanced Practice Provider (APP) C...
Maryland Public Television earns 20 regional Emmy® Awards
OWINGS MILLS, MD, June 22, 2026 (GLOBE NEWSWIRE) -- The National Capital Chesapeake Bay Chapter of the National Academy of Television Arts & Sciences presented Maryland Public Television with 20 Emmys...
New Anglia University Responds to Rising Competition for Medical School Places in the UK
George Hill, Anguilla, 17 June 2026 -- As competition for medical school places in the United Kingdom reaches unprecedented levels, New Anglia University is providing aspiring doctors with an alternat...
Onera Will Showcase Its Onera hPSG® Solution at the SLEEP 2026 Conference June 14-17, 2026 in Baltimore, MD, USA.
EINDHOVEN, Netherlands--(BUSINESS WIRE)-- #MedicalDevice--Onera Health, a leader in transforming sleep medicine, announces that its end-to-end home polysomnography solution, the Onera hPSG® solution, ...
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or “Tempest Therapeutics”) today announced the appointment of two independent directors, Drake R...
Pediatrix Medical announces publication of research on NEC in preterm infants
Pediatrix Medical (MD) Group announced the publication of new research on probiotic use and necrotizing enterocolitis in preterm infants, addressing pressing questions about one of the most controvers...
Pediatrix Medical Group Announces Publication of New Research Addressing Urgent Questions in Neonatology
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Announces Publication of New Research Addressing Urgent Questions in Neonatology.
HSS Chief of Sports Medicine, Riley J. Williams III, MD, Named FIFA Venue Medical Officer for the 2026 World Cup
NEW YORK--(BUSINESS WIRE)--FIFA World Cup 26™ has named Hospital for Special Surgery (HSS), ranked No. 1 in orthopedics nationally by U.S. News & World Report (2024–2025), Sports Medicine Surgeon, Ril...
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Passkey Therapeutics Appoints Mandeep Kaur, MD, MS, as Chief Medical Officer to Advance Clinical Validation of Its Computational Genetics-Based Novel Drug Combination Platform
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Passkey Therapeutics, the architect of the Locksmith® platform for systematically identifying new therapeutic opportunities from synergistic drug combinations, today...
Pediatrix Medical price target raised to $25 from $22 at UBS
UBS raised the firm’s price target on Pediatrix Medical (MD) to $25 from $22 and keeps a Neutral rating on the shares.
Pediatrix Medical price target raised to $24 from $21 at Mizuho
Mizuho raised the firm’s price target on Pediatrix Medical (MD) to $24 from $21 and keeps a Neutral rating on the shares.
Pediatrix Medical Group Earnings Call Transcript: Q1 2026
Q1 delivered strong adjusted EBITDA of $58M, driven by 4% pricing growth and favorable payer mix, offsetting modest volume declines. Full-year adjusted EBITDA guidance of $280M–$300M is reaffirmed, with pricing expected to remain flat as RCM cash collection impact tapers.
Pediatrix Medical Group Quarterly report: Q1 2026
Pediatrix Medical Group has published its Q1 2026 quarterly earnings report on May 5, 2026.